4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Lags Revenue Estimates
FDMT4D Molecular Therapeutics(FDMT) ZACKS·2024-08-09 06:56

4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of 0.63pershareversustheZacksConsensusEstimateofalossof0.63 per share versus the Zacks Consensus Estimate of a loss of 0.72. This compares to loss of 0.77pershareayearago.Thesefiguresareadjustedfornon−recurringitems.Thisquarterlyreportrepresentsanearningssurpriseof12.500.77 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 12.50%. A quarter ago, it was expected that this company would post a loss of 0.73 per share when it actually produced a loss of $0.66, delivering a surprise of 9.59%.Over the last four quarters, the compa ...